Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

MDS 2020 | HMAs are the standard, what are their limitations?

Alan List, MD, Tampa, FL, discusses the use of hypomethylating agents (HMAs) in the treatment of myelodysplastic syndromes (MDS), their limitations and how trials are seeking to diminish this unmet need. This interview took place at the 2nd Regional Symposium on Myelodysplastic Syndromes (MDS 2020), held in Tel Aviv, Israel.